Play all audios:
Rise and shine, everyone, another busy day is on the way. After all, this is the middle of the week, which means we still have some mountains to climb. In our case, this means rifling
through documents and talking to interesting people as we race to meet deadlines. To cope, yes, we are quaffing cups of stimulation. Our flavor this week is Cinnamon Dolce for those seeking
a recommendation. Meanwhile, here are your tidbits. Hope you survive … EXPRESS SCRIPTS RECEIVED SUBPOENAS REQUESTING INFORMATION ABOUT ITS RELATIONSHIPS WITH DRUG MAKERS, HEALTH PLANS,
CHARITABLE FOUNDATIONS, AND SPECIALTY PHARMACIES, according to a filing with the Securities and Exchange Commission. The demands, which can be seen on page 41, were made over the past two
months by the Department of Justice, and US attorneys in New York and Boston. NOVARTIS CHIEF EXECUTIVE JOE JIMENEZ EXPECTS A MORE DIFFICULT PRICING ENVIRONMENT FOR DRUGS IN THE US IN COMING
YEARS, Reuters writes. Last week, Roche chief executive Severin Schwan said he does not see a “fundamental change” in US pricing pressure after the coming presidential election, regardless
of which candidate wins. So which CEO is correct? STAT+ Exclusive Story Already have an account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS IN-DEPTH
ANALYSIS, NEWSLETTERS, PREMIUM EVENTS, AND NEWS ALERTS. Already have an account? Log in Individual plans Group plans View All Plans To read the rest of this story subscribe to STAT+.
Subscribe